The company has acquired business assets of the pharmaceutical manufacturing unit of Acacia Lifesciences with effect from October 1, on a going concern basis, Biocon said in a regulatory filing.
"This unit is presently manufacturing advanced intermediates of potent active pharma ingredients (APIs) useful to the company's business as well as for supply to third party customers," it added.
The US Food and Drug Administration (USFDA) approved facility would help the Bangalore-based company in vertically integrating its oncology related abbreviated new drug application (ANDA) filings in the future.
Biocon shares today ended at Rs 447.60 apiece on the BSE, up 0.90 per cent from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
